Kalaris Therapeutics Stock Jumps 47.8% Post-Merger, Secures $100M for TH103 Phase 1

Introduction

Kalaris Therapeutics Inc. (Nasdaq: KLRS) is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for retinal diseases. Founded by leaders in ophthalmology drug development, the company's lead candidate, TH103, is a fully humanized, recombinant fusion protein engineered as a long-acting anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) and other exudative retinal conditions.

Corporate Structure and Leadership

Kalaris is headquartered on the Nasdaq Global Market and supported by investors with experience in retina therapeutics. The company does not publicly disclose its total headcount, but its management and board include individuals from leading biopharmaceutical and ophthalmology organizations:

• Andrew Oxtoby, Chief Executive Officer (Eli Lilly, Aimmune, Chinook)
• Matthew Feinsod, M.D., Chief Medical Officer (Genentech/Roche, Eyetech, AGTC)
• Kristine Curtiss, SVP Clinical (iSTAR Medical, Iveric Bio)
• Brett Hagen, CPA, SVP Finance & CAO (AlloVir Inc., Eloxx)
• Jill Porter, VP Chemistry, Manufacturing & Controls (Roche, OxThera)
• Nancy Davis, VP Clinical Operations (Novartis, Aerie)

The board is chaired by David Hallal and includes co-founders Dr. Napoleone Ferrara and other industry leaders from Genentech, Samsara Biocapital, and F2 Ventures.

Retinal therapy by v2osk

Recent Developments

In November 2024, Kalaris announced a merger with AlloVir Inc.; the transaction closed in mid-2025, creating a combined company with approximately US$100 million in cash to fund operations into the fourth quarter of 2026. Following the merger, KLRS shares began trading on the Nasdaq Global Market.

In May and June 2025, members of Kalaris’s management team participated in industry and investor forums:

• May 27, 2025: Stifel 2025 Virtual Ophthalmology Forum
• June 5, 2025: Noble Capital Markets Emerging Growth Virtual Equity Conference

The company’s Phase 1 clinical trial of TH103 in treatment-naïve nAMD patients is ongoing, with initial safety, pharmacokinetics, and preliminary efficacy data expected in the second half of 2025.

Financial and Strategic Analysis

As of September 3, 2025, KLRS closed at US$5.91, with a one-day increase of 47.75%, on a trading volume of 671,652 shares. According to Yahoo Finance data, the company’s market capitalization is approximately US$76 million, with total cash of US$88.4 million reported in the trailing twelve months and a net loss of US$81.7 million.

Kalaris’s strategic priorities include:
• Advancing TH103 through clinical development toward Phase 2 trials
• Managing cash runway through the merger-enhanced balance sheet
• Engaging investors via conference presentations and regulatory updates

The August 13, 2025 10-Q filing provides a detailed overview of operating expenses, research and development costs, and cash position, supporting the company’s funding plan through late 2026.

Market Position and Industry Context

Current standard-of-care anti-VEGF agents—Avastin and Lucentis—require frequent intravitreal injections and clinic visits, which may lead to missed doses and suboptimal outcomes. TH103 is designed for extended intraocular retention by binding both VEGF-A and heparan sulfate proteoglycans, with the potential to reduce injection frequency. Should Phase 1/2 results confirm its extended activity and safety profile, Kalaris plans to address a significant unmet need in the retinal disease market.

tl;dr

Kalaris completed its merger with AlloVir in mid-2025, secured approximately US$100 million in cash, and began trading as KLRS on Nasdaq. The company is enrolling patients in a Phase 1 trial of TH103 for nAMD, with data anticipated in the second half of 2025. Its balance sheet is funded through Q4 2026, positioning Kalaris to advance TH103 toward Phase 2 studies.